William Chen Wei Ning on Pharmacogenetics and Pharmacoproteomics Analysis of Patients on Warfarin Anticoagulant Therapy: identification of potential biomarker

In Clinical Trials by valerie limLeave a Comment

Professor William Chen Wei Ning, Professor at School of Chemical and Biomedical Engineering, Nanyang Technological University, Singapore will be presenting at BioPharma Asia Convention‘s on floor seminar on 21 March 2012 at 1.30pm on Pharmacogenetics and Pharmacoproteomics Analysis of Patients on Warfarin Anticoagulant Therapy: identification of potential biomarker.

As a scholar, he received his Bachelor and PhD degrees in Molecular Biology from Université Catholique de Louvain (Belgium). His research is largely interdisciplinary with strong focus on virusâ€host interactions, and biomarker discovery for pharmaceutical applications. He has been active as Principal Investigator of research grants, and has published over 115 top quality international journal papers. He is also inventor of a number of patents. He has regularly been invited to speak at international conferences and serves on the editorial board of six international journals. He is a recipient of a number of awards in recognition of his contribution to education and research.

The following would be an excerpt of what he would be presenting:

Recognizing specific protein changes in response to drug administration in humans has the potential for the development of personalized medicine. Such changes can be identified by pharmacoproteomics approach based on proteomic technologies. It can also be helpful in matching a particular targetâ€based therapy to a particular marker in a subgroup of patients, in addition to the profile of genetic polymorphism. Warfarin is a commonly prescribed oral anticoagulant in patients with prosthetic valve disease, venous thromboembolism and stroke. METHODS AND
We used a combined pharmacogenetics and iTRAQâ€coupled LCâ€MS/MS pharmacoproteomics approach to analyze plasma protein profiles of 53 patients, and identified significantly upregulated level of transthyretin precursor in patients receiving low dose of warfarin but not in those on high dose of warfarin. In addition, realâ€time RTâ€PCR, western blotting, human ILâ€6 ELISA assay were done for the results validation.
This combined pharmacogenomics and pharmacoproteomics approach may be applied for other targetbased therapies, in matching a particular marker in a subgroup of patients, in addition to the profile of genetic polymorphism.

Don’t miss out this opportunity to listen to Prof Chen share his expertise on Pharmacogenetics and Pharmacoproteomics Analysis of Patients on Warfarin Anticoagulant Therapy: identification of potential biomarker. Pre-register to attend this talk by Professor William Chen today.

Leave a Comment

Current ye@r *